[Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
de Clercq
E
E
Rega Institute for Medical Research, K.U. Leuven, Belgique.
Snoeck
R
R
D000081:Acetamides / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D066298:In Vitro Techniques; D019829:Nevirapine; D017646:Organosilicon Compounds; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology; D012194:RNA-Directed DNA Polymerase / Q000378:metabolism*; D018894:Reverse Transcriptase Inhibitors; D012825:Silicon / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000081:Acetamides; D000998:Antiviral Agents; D001570:Benzodiazepinones; D017646:Organosilicon Compounds; D010879:Piperazines; D011725:Pyridines; D011728:Pyridones; D018894:Reverse Transcriptase Inhibitors; C009660:t-butyldimethylsilyl compounds; D019829:Nevirapine; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D012825:Silicon